Biotech | March 11, 2022
Moderna begins Phase 2 study of Omicron-specific bivalent booster
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte
As a part of its CSR initiatives, the ‘Healthcare Heroes of India’ Awards by Metropolis aims to identify and recognize those individuals and institutions in healthcare sector with a strong sense of purpose and commitment towards patient care and who have prioritized it over all other growth parameters
Subscribe To Our Newsletter & Stay Updated
